Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Versus Placebo in Macular Telangiectasia Type 1
NCT03845049Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2019
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in macular edema (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Change in Central Retinal Thickness at 6 months. Started Jul 2019; status: terminated.
02
Drugs
aflibercept
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT03845049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845049.